Recentin (cediranib) / AstraZeneca - LARVOL DELTA

Advancing precision cancer medicine with patient-derived organoids: an endometrial cancer case study (AACR 2025) - "We demonstrate the potential of PDO models in cancer research. By leveraging RNAseq, ATACseq, and high-throughput drug screening, this study identified actionable targets in the VEGF and PI3K pathways and validated the synergistic effects of Cediranib and BKM120 in an endometrial cancer with complex histology and genomic profile. These findings highlight the value of PDO models as innovative tools for personalizing cancer treatment and developing effective therapies for complex endometrial malignancies."

Case study • Clinical • Endometrial Cancer • Gynecologic Cancers • Oncology • Solid Tumor • ARID1A • CTNNB1 • PIK3CA

Neoadjuvant olaparib and cediranib in renal cancer: Outcomes of the WIndow-of-opportunity in REnal cancer (WIRE) Trial (AACR 2025) - P2 | "Positive responses in median Ktrans were observed in both the cediranib monotherapy and cediranib and olaparib combination therapy arms. Therapy was well tolerated, with no substantial toxicity or delays to surgery. Greater induction of angiogenic factors in the combination arm indicates possible synergy between cediranib and olaparib."

Clinical • Clear Cell Renal Cell Carcinoma • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

In vivo, ex vivo, and in vitro (2D and 3D) tumor models: Uses, strengths and limitations (AACR 2025) - "The 138582-377-R Merkel cell (PDX) treated with cediranib (6 mg/kg) & erlotinib (90 mg/kg) Q5D for 3 wks resulted in 80% decrease in tumor vol compared with controls & 80% cytotoxicity in complex spheroids from the same tumor. Less than 90% cytotoxicity was achieved in the complex spheroids in the estimated clinical Cmax concentration range of entinostat. The combination of ipatasertib (60 mg/kg) & selumetinib (20 mg/kg) administered twice per day for 2-rounds of 10 days was less effective in the 171881-019-R breast ca PDX and the 845751-090-R head & neck squamous ca PDX than would be predicted by the complex spheroid studies."

Preclinical • Oncology • Solid Tumor

Molecular correlates of response in patients with metastatic castration-resistant prostate cancer treated with olaparib with or without cediranib (NCI9984). (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

SWOG S0905: Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (clinicaltrials.gov) - P1/2 | N=117 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Epithelioid Mesothelioma • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Sarcoma • Sarcomatoid Mesothelioma • Solid Tumor

A clinical study of mitoxantrone liposome, chidamide combined with lenalidomide in the treatment of angioimmunoblastic T-cell lymphoma (AITL) (ChiCTR) - P=N/A | N=15 | Not yet recruiting | Sponsor: THE FIRST HOSPITAL OF LANZHOU UNVERSITY; THE FIRST HOSPITAL OF LANZHOU UNVERSITY

New trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Comparing durvalumab, olaparib, and cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior bevacizumab: the phase II NRG-GY023 trial. (PubMed, Clin Cancer Res) - "In PROC patients with prior bevacizumab, all experimental arms failed to reach the primary objective of improving PFS compared with SOC."

Journal • Monotherapy • P2 data • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

Machine learning-based in-silico analysis identifies signatures of lysyl oxidases for prognostic and therapeutic response prediction in cancer. (PubMed, Cell Commun Signal) - "Our study provides novel insights into the potential value of LOX/LOXL in cancer pathogenesis and treatment, and particularly its prognostic significance in glioma."

Journal • Bladder Cancer • Brain Cancer • CNS Tumor • Glioma • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • LOX • LOXL2

Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial. (PubMed, Int J Gynecol Cancer) - P2 | "The unexpectedly high withdrawal rate during paclitaxel alone, before introducing cediranib, meant we were unable to definitely conclude that paclitaxel plus cediranib did not cause gastrointestinal perforation or fistula. The regimen was however tolerated."

Journal • P2 data • Platinum resistant • Fatigue • Gastrointestinal Disorder • Oncology • Ovarian Cancer • Solid Tumor

DAPPER: Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: University Health Network, Toronto | Trial completion date: Jan 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Colorectal Cancer • Hepatology • Leiomyosarcoma • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Sarcoma • Solid Tumor • HRD

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... (clinicaltrials.gov) - P1/2 | N=268 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2026 ➔ Jul 2026 | Trial primary completion date: Mar 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • ALK • BRAF • BRCA1 • BRCA2 • EGFR • HER-2 • PGR

Development of indole hybrids for potential lung cancer treatment - part II. (PubMed, Future Med Chem) - "Moreover, indole hybrids osimertinib, mobocertinib, cediranib, and vizimpro are currently applied in clinics for lung cancer therapy, demonstrating that indole hybrids are valuable scaffolds in the treatment and eradication of lung cancer. This review provides a comprehensive overview of the evolving landscape of indole hybrids with the in vitro and in vivo efficacy against lung cancer, and the structure-activity relationships as well as mechanisms of action are also discussed, covering articles published from 2021 onward."

Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

NCI-2019-04148: Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Mar 2025 ➔ Dec 2027 | Trial primary completion date: Mar 2025 ➔ Dec 2027

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • BRCA • ER • HER-2

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies (clinicaltrials.gov) - P1 | N=19 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=155 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Breast Cancer • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor • Triple Negative Breast Cancer • BRCA • MUC16

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma (clinicaltrials.gov) - P2 | N=53 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed

Trial completion • Alveolar Soft Tissue Sarcoma • Oncology • Sarcoma • Solid Tumor

COMICE: A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer (clinicaltrials.gov) - P2 | N=79 | Active, not recruiting | Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust | Trial completion date: Sep 2021 ➔ Mar 2026 | Trial primary completion date: Aug 2021 ➔ Mar 2025 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor • BRCA

A Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials. (PubMed, Cancers (Basel)) - "Our analysis indicates that, in patients with unresectable pleural mesothelioma, three of the five novel treatments provided a significant survival benefit compared with the standard of care. Further research is needed to confirm the OS benefit found in our analysis with some treatments, whereas cisplatin alone and cediranib plus pemetrexed+cisplatin with maintenance with cediranib do not seem to deserve further research."

Journal • Retrospective data • Review • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Solid Tumor

NCI-2017-01672: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (clinicaltrials.gov) - P2 | N=286 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2024 ➔ Jan 2026

Trial completion date • Endometrial Adenocarcinoma • Endometrial Cancer • Endometrial Serous Adenocarcinoma • Oncology • Solid Tumor • Uterine Cancer

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours (clinicaltrials.gov) - P1 | N=64 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Oncology • Prostate Cancer • Solid Tumor

HUDSON: Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (clinicaltrials.gov) - P2 | N=531 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Sep 2024 ➔ Sep 2026 | Trial primary completion date: Sep 2024 ➔ Sep 2026

Biomarker • IO biomarker • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BAROCCO: Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib (clinicaltrials.gov) - P2 | N=123 | Completed | Sponsor: Mario Negri Institute for Pharmacological Research | Unknown status ➔ Completed

Trial completion • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... (clinicaltrials.gov) - P1/2 | N=257 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Active, not recruiting | N=384 ➔ 257 | Trial completion date: Dec 2025 ➔ Dec 2026

Enrollment change • Enrollment closed • Trial completion date • Breast Cancer • Colorectal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • ALK • BRAF • BRCA1 • BRCA2 • EGFR • HER-2 • PGR

Regulation and Function of CCL2 and N-Myc in Retinoic Acid-treated Neuroblastoma Cells. (PubMed, Cancer Genomics Proteomics) - "CCL2 and N-Myc promote the viability of RA-treated cells, although the levels of these mediators were not consistently correlated with cellular outcomes, especially during apoptotic signaling."

Journal • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor • CCL2 • MYCN

protein kinase inhibitors as Targeted therapy for glioblastoma: A meta-analysis of randomized controlled clinical trials. (PubMed, Pharmacol Res) - "The standard treatment for newly diagnosed GBM includes surgical resection, when feasible, followed by radiotherapy and temozolomide-based chemotherapy. Upon disease progression, the anti-vascular endothelial growth factor-A (VEGF-A) monoclonal antibody bevacizumab, can be considered...For instance, when comparing PKI treatment with other treatments, median OS and PFS showed no significant difference (-0.78 months, 95% CI, -2.12-0.55, p=0.25; -0.23 months, 95% CI, -0.79-0.34, p=0.43, respectively), and similar non-significant results were observed in the pooled analyses (OS: HR=0.89, 95% CI, 0.59-1.32, p=0.55; PFS: HR=0.83, 95% CI, 0.63-1.11, p=0.21). Despite these overall negative findings, some data indicate improved clinical outcomes in a subset of GBM patients treated with certain PKIs (i.e., regorafenib) and encourage further research to identify PKIs with better blood-brain barrier penetration and lower risk for resistance development."

Clinical • Journal • Retrospective data • Review • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor